Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. [electronic resource]
Producer: 20150806Description: 474 p. digitalISSN:- 1745-6215
- Antineoplastic Agents -- adverse effects
- Carcinoma, Hepatocellular -- economics
- Clinical Protocols
- Cost-Benefit Analysis
- Disease Progression
- Disease-Free Survival
- Drug Costs
- Embolization, Therapeutic -- adverse effects
- France
- Humans
- Liver Neoplasms -- economics
- Microspheres
- Niacinamide -- adverse effects
- Phenylurea Compounds -- adverse effects
- Prospective Studies
- Protein Kinase Inhibitors -- adverse effects
- Quality of Life
- Research Design
- Sorafenib
- Time Factors
- Treatment Outcome
- Yttrium Radioisotopes -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.